Review article

DO WE KNOW ALL EFFECTS OF HEPARINS IN HEMODIALYZED PATIENTS?

MILENKA ŠAIN ; Split University Hospital Center, Department of Nephrology and Dialysis, School of Medicine, University of Split, Split, Croatia
DRAGAN LJUTIć ; Split University Hospital Center, Department of Nephrology and Dialysis, School of Medicine, University of Split, Split, Croatia
VEDRAN KOVAčIć ; Split University Hospital Center, Department of Nephrology and Dialysis, School of Medicine, University of Split, Split, Croatia
JOSIPA RADIć ; Split University Hospital Center, Department of Nephrology and Dialysis, School of Medicine, University of Split, Split, Croatia
IVO JELIčIć ; Split University Hospital Center, Department of Nephrology and Dialysis, School of Medicine, University of Split, Split, Croatia

Abstract

Anticoagulation with heparins during hemodialysis (HD) is aimed at preventing the activation of coagulation in the extracorporeal circuit. As HD patients are exposed to unfractionated and low molecular weight heparins (LMWH) for years, non-hemorrhagic effects (osteoporosis, reduction of elevated blood pressure, with lesser intra- and interdialytic hypotensive episodes, effects on brain microvascular circulation and decreasing vascular dementia and Alzheimer’s disease, and chronic and malignant diseases) require new trials with individualized doses of heparins

Keywords

anticoagulation; low molecular weight heparin; hemodialysis

Hrčak ID:

97570

URI

https://hrcak.srce.hr/97570

Publication date:

14.2.2013.

Article data in other languages: croatian

Visits: 3.471 *